BNT211 (CAR-T + mRNA Vaccine for Solid Tumors)
Claudin-6 positive solid tumors
SponsorBioNTech
180Enrollment Target
22Trial Sites
3Countries
September 2027Est. Completion
About This Trial
First-in-class combination of CAR-T cells with mRNA vaccine boosting targeting Claudin-6 in ovarian, testicular, and lung cancers.
Primary Endpoints
- Overall response rate
- CAR-T cell persistence
Latest Update
February 2026
59% objective response rate in evaluable patients. Complete responses seen in 3 ovarian cancer patients.